The Clinicopathological Features and Survival of Castleman Disease: a Multicenter Turkish Study
dc.authorid | Yilmaz, Fatma/0000-0001-6112-3950 | |
dc.authorid | Yilmaz, Farise/0000-0001-8136-513X | |
dc.authorid | Eser, Bulent/0000-0002-4513-3486 | |
dc.authorscopusid | 57193709115 | |
dc.authorscopusid | 57210186649 | |
dc.authorscopusid | 57188728728 | |
dc.authorscopusid | 57251124400 | |
dc.authorscopusid | 59109204200 | |
dc.authorscopusid | 57194114271 | |
dc.authorscopusid | 6603662687 | |
dc.authorwosid | Korkmaz, Serdal/Ist-3736-2023 | |
dc.authorwosid | Yılmaz, Fatma/Acx-9470-2022 | |
dc.authorwosid | Erkurt, Mehmet/Abi-7232-2020 | |
dc.authorwosid | Altuntas, Fevzi/E-8945-2015 | |
dc.authorwosid | Bagci, Metin/Aad-2427-2020 | |
dc.authorwosid | Ulas, Turgay/A-6050-2018 | |
dc.authorwosid | Albayrak, Murat/Juu-5382-2023 | |
dc.contributor.author | Yildiz, J. | |
dc.contributor.author | Bagci, M. | |
dc.contributor.author | Sayin, S. | |
dc.contributor.author | Kaya, A. | |
dc.contributor.author | Yilmaz, F. | |
dc.contributor.author | Ekinci, O. | |
dc.contributor.author | Altuntas, F. | |
dc.date.accessioned | 2025-05-10T16:54:05Z | |
dc.date.available | 2025-05-10T16:54:05Z | |
dc.date.issued | 2022 | |
dc.department | T.C. Van Yüzüncü Yıl Üniversitesi | en_US |
dc.department-temp | Yildiz J., Department of Hematology, Yenimahalle Training and Research Hospital, Yildirim Beyazit University, Ankara, Turkey; Bagci M., Department of Hematology, Selcuk University, Konya, Turkey; Sayin S., Department of Hematology, Selcuk University, Konya, Turkey; Kaya A., Department of Hematology, Celal Bayar University, Manisa, Turkey; Yilmaz F., Department of Hematology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; Ekinci O., University of Health Sciences, Gazi Yasargil Training and Research Hospital, Department of Hematology, Diyarbakir, Turkey; Dal M.S., Department of Hematology and Apheresis, Unit University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey; Basturk A., Medicana International Istanbul Hospital, Istanbul, Turkey; Aydogdu I., Department of Hematology, Celal Bayar University, Manisa, Turkey; Albayrak M., Department of Hematology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; Dogan A., Department of Hematology, Yuzuncu Yil University, Van, Turkey; Erkurt M.A., Department of Hematology, Inonu University, Malatya, Turkey; Korkmaz S., Department of Hematology and Apheresis Unit, University of Health Sciences, Kayseri City Training and Research Hospital, Kayseri, Turkey; Ulas T., Department of Internal Medicine, Division of Hematology, Near East University, School of Medicine, Nicosia, Cyprus; Eser B., Department of Hematology, Medical Park Antalya Hospital, Antalya, Turkey; Altuntas F., Department of Internal Medicine, Division of Hematology, Ankara Yildirim Beyazit University, School of Medicine, Ankara, Turkey | en_US |
dc.description.abstract | Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved. | en_US |
dc.description.woscitationindex | Science Citation Index Expanded | |
dc.identifier.doi | 10.26355/eurrev_202202_28103 | |
dc.identifier.endpage | 1137 | en_US |
dc.identifier.issn | 1128-3602 | |
dc.identifier.issue | 4 | en_US |
dc.identifier.pmid | 35253168 | |
dc.identifier.pmid | 35253168 | |
dc.identifier.scopus | 2-s2.0-85125881550 | |
dc.identifier.scopusquality | Q2 | |
dc.identifier.startpage | 1131 | en_US |
dc.identifier.uri | https://doi.org/10.26355/eurrev_202202_28103 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14720/3012 | |
dc.identifier.volume | 26 | en_US |
dc.identifier.wos | WOS:000763332500012 | |
dc.identifier.wosquality | Q2 | |
dc.language.iso | en | en_US |
dc.publisher | Verduci Editore s.r.l | en_US |
dc.relation.ispartof | European Review for Medical and Pharmacological Sciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Cd | en_US |
dc.subject | Hyaline Vascular | en_US |
dc.subject | Multicentric Castleman Disease | en_US |
dc.subject | Unicentric Castleman Disease | en_US |
dc.title | The Clinicopathological Features and Survival of Castleman Disease: a Multicenter Turkish Study | en_US |
dc.type | Article | en_US |